The vascular endothelium in diabetes: A practical target for drug treatment?

Karen L. Andrews, Malarvannan Pannirselvam, Todd J. Anderson, Alicia J. Jenkins, Christopher Triggle, Michael A. Hill

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Vascular disease remains a major cause of morbidity and mortality in diabetes mellitus, in spite of recent improvements in outcome, some of which may be modulated by improved endothelial function. Therapeutic strategies aimed directly at preventing, or minimising the extent of, these sequelae are required as an adjunct to treatments directed at normalising the metabolic milieu. The microvasculature, and the endothelium in particular, are early contributors to vascular dysfunction, thus raising the question as to how best to specifically target the endothelium. However, the expansive nature of the microvasculature, the varying demands that tissues have in terms of blood flow, and the heterogeneity that exists amongst cell types in different sites raises potential problems as to the practicality of such an approach. Furthermore, temporal and genetic factors in the genesis of diabetic microvascular dysfunction may impact on therapeutic strategies. It is suggested that a systematic approach is required to understand the heterogeneity of the microvasculature, with particular emphasis on relating differences in gene and protein expression with functional properties. Such an approach may then provide the necessary information to allow exploitation of endothelial cell heterogeneity for unique targeted interventions, as well as providing the necessary rationale for pharmacological interventions (both prophylactic and corrective) aimed at the endothelium as a whole.

Original languageEnglish
Pages (from-to)101-117
Number of pages17
JournalExpert Opinion on Therapeutic Targets
Volume9
Issue number1
DOIs
Publication statusPublished - Feb 2005
Externally publishedYes

Fingerprint

Drug therapy
Endothelial cells
Vascular Endothelium
Medical problems
Microvessels
Endothelium
Blood
Tissue
Pharmaceutical Preparations
Proteins
Vascular Diseases
Blood Vessels
Diabetes Mellitus
Endothelial Cells
Pharmacology
Morbidity
Gene Expression
Mortality
Therapeutics

Keywords

  • Diabetes
  • Endothelial dysfunction
  • Hyperglycaemia
  • Therapeutic targets
  • Vascular complications

ASJC Scopus subject areas

  • Molecular Medicine
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The vascular endothelium in diabetes : A practical target for drug treatment? / Andrews, Karen L.; Pannirselvam, Malarvannan; Anderson, Todd J.; Jenkins, Alicia J.; Triggle, Christopher; Hill, Michael A.

In: Expert Opinion on Therapeutic Targets, Vol. 9, No. 1, 02.2005, p. 101-117.

Research output: Contribution to journalReview article

Andrews, Karen L. ; Pannirselvam, Malarvannan ; Anderson, Todd J. ; Jenkins, Alicia J. ; Triggle, Christopher ; Hill, Michael A. / The vascular endothelium in diabetes : A practical target for drug treatment?. In: Expert Opinion on Therapeutic Targets. 2005 ; Vol. 9, No. 1. pp. 101-117.
@article{44450c1fedff413593f85b8a9c324db0,
title = "The vascular endothelium in diabetes: A practical target for drug treatment?",
abstract = "Vascular disease remains a major cause of morbidity and mortality in diabetes mellitus, in spite of recent improvements in outcome, some of which may be modulated by improved endothelial function. Therapeutic strategies aimed directly at preventing, or minimising the extent of, these sequelae are required as an adjunct to treatments directed at normalising the metabolic milieu. The microvasculature, and the endothelium in particular, are early contributors to vascular dysfunction, thus raising the question as to how best to specifically target the endothelium. However, the expansive nature of the microvasculature, the varying demands that tissues have in terms of blood flow, and the heterogeneity that exists amongst cell types in different sites raises potential problems as to the practicality of such an approach. Furthermore, temporal and genetic factors in the genesis of diabetic microvascular dysfunction may impact on therapeutic strategies. It is suggested that a systematic approach is required to understand the heterogeneity of the microvasculature, with particular emphasis on relating differences in gene and protein expression with functional properties. Such an approach may then provide the necessary information to allow exploitation of endothelial cell heterogeneity for unique targeted interventions, as well as providing the necessary rationale for pharmacological interventions (both prophylactic and corrective) aimed at the endothelium as a whole.",
keywords = "Diabetes, Endothelial dysfunction, Hyperglycaemia, Therapeutic targets, Vascular complications",
author = "Andrews, {Karen L.} and Malarvannan Pannirselvam and Anderson, {Todd J.} and Jenkins, {Alicia J.} and Christopher Triggle and Hill, {Michael A.}",
year = "2005",
month = "2",
doi = "10.1517/14728222.9.1.101",
language = "English",
volume = "9",
pages = "101--117",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - The vascular endothelium in diabetes

T2 - A practical target for drug treatment?

AU - Andrews, Karen L.

AU - Pannirselvam, Malarvannan

AU - Anderson, Todd J.

AU - Jenkins, Alicia J.

AU - Triggle, Christopher

AU - Hill, Michael A.

PY - 2005/2

Y1 - 2005/2

N2 - Vascular disease remains a major cause of morbidity and mortality in diabetes mellitus, in spite of recent improvements in outcome, some of which may be modulated by improved endothelial function. Therapeutic strategies aimed directly at preventing, or minimising the extent of, these sequelae are required as an adjunct to treatments directed at normalising the metabolic milieu. The microvasculature, and the endothelium in particular, are early contributors to vascular dysfunction, thus raising the question as to how best to specifically target the endothelium. However, the expansive nature of the microvasculature, the varying demands that tissues have in terms of blood flow, and the heterogeneity that exists amongst cell types in different sites raises potential problems as to the practicality of such an approach. Furthermore, temporal and genetic factors in the genesis of diabetic microvascular dysfunction may impact on therapeutic strategies. It is suggested that a systematic approach is required to understand the heterogeneity of the microvasculature, with particular emphasis on relating differences in gene and protein expression with functional properties. Such an approach may then provide the necessary information to allow exploitation of endothelial cell heterogeneity for unique targeted interventions, as well as providing the necessary rationale for pharmacological interventions (both prophylactic and corrective) aimed at the endothelium as a whole.

AB - Vascular disease remains a major cause of morbidity and mortality in diabetes mellitus, in spite of recent improvements in outcome, some of which may be modulated by improved endothelial function. Therapeutic strategies aimed directly at preventing, or minimising the extent of, these sequelae are required as an adjunct to treatments directed at normalising the metabolic milieu. The microvasculature, and the endothelium in particular, are early contributors to vascular dysfunction, thus raising the question as to how best to specifically target the endothelium. However, the expansive nature of the microvasculature, the varying demands that tissues have in terms of blood flow, and the heterogeneity that exists amongst cell types in different sites raises potential problems as to the practicality of such an approach. Furthermore, temporal and genetic factors in the genesis of diabetic microvascular dysfunction may impact on therapeutic strategies. It is suggested that a systematic approach is required to understand the heterogeneity of the microvasculature, with particular emphasis on relating differences in gene and protein expression with functional properties. Such an approach may then provide the necessary information to allow exploitation of endothelial cell heterogeneity for unique targeted interventions, as well as providing the necessary rationale for pharmacological interventions (both prophylactic and corrective) aimed at the endothelium as a whole.

KW - Diabetes

KW - Endothelial dysfunction

KW - Hyperglycaemia

KW - Therapeutic targets

KW - Vascular complications

UR - http://www.scopus.com/inward/record.url?scp=14744290528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744290528&partnerID=8YFLogxK

U2 - 10.1517/14728222.9.1.101

DO - 10.1517/14728222.9.1.101

M3 - Review article

C2 - 15757485

AN - SCOPUS:14744290528

VL - 9

SP - 101

EP - 117

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -